FANCA mutation
|
Prostate Cancer
|
FANCA mutation
|
Prostate Cancer
|
rucaparib Sensitive: C2 – Inclusion Criteria
|
rucaparib Sensitive: C2 – Inclusion Criteria
|
FANCA mutation
|
Prostate Cancer
|
FANCA mutation
|
Prostate Cancer
|
PARP inhibitor Sensitive: C3 – Early Trials
|
PARP inhibitor Sensitive: C3 – Early Trials
|
FANCA mutation
|
HER2 Negative Breast Cancer
|
FANCA mutation
|
HER2 Negative Breast Cancer
|
talazoparib Sensitive: C3 – Early Trials
|
talazoparib Sensitive: C3 – Early Trials
|
FANCA mutation
|
CRC
|
FANCA mutation
|
CRC
|
sintilimab + fruquintinib Resistant: C3 – Early Trials
|
sintilimab + fruquintinib Resistant: C3 – Early Trials
|
FANCA mutation
|
Prostate Cancer
|
FANCA mutation
|
Prostate Cancer
|
rucaparib + copanlisib Sensitive: C3 – Early Trials
|
rucaparib + copanlisib Sensitive: C3 – Early Trials
|
FANCA mutation
|
Ovarian Cancer
|
FANCA mutation
|
Ovarian Cancer
|
niraparib Sensitive: C4 – Case Studies
|
niraparib Sensitive: C4 – Case Studies
|